Incyte Pins Hopes On Phase III Jakafi Analysis In COVID-19 ARDS
Phase III Overall Negative, But Successful On Subset And Post-Hoc Analyses
Drugs for ARDS in COVID-19 have yielded mixed results in the clinic, with Boehringer Ingelheim pulling one from Phase II development earlier this month.
